TECH

Business Context and Reporting Period

Company: BIO-TECHNE Corp (Ticker: TECH)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year ended June 30, 2025
Business Overview: Bio-Techne develops, manufactures, and sells life science reagents, instruments, and services for research, diagnostics, and bioprocessing markets. The company operates through two segments: Protein Sciences (72% of net sales) and Diagnostics and Spatial Biology (28% of net sales). The company is headquartered in Minneapolis, Minnesota, and operates globally.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Consolidated net sales increased 5% to $1.2 billion, driven by 5% organic growth. The Protein Sciences segment grew 5%, while the Diagnostics and Spatial Biology segment grew 6%.
• Earnings Decline: GAAP net earnings decreased 56% year-over-year. This decline was primarily due to non-recurring items, including a $41.8 million litigation charge (arbitration award), an $80.5 million impairment of assets held-for-sale, and restructuring costs.
• Adjusted Earnings: Excluding non-recurring items, adjusted net earnings increased 8% year-over-year, reflecting favorable volume leverage in the Protein Sciences segment.
• Margin Compression: GAAP gross margin decreased to 64.8% from 66.4%, impacted by the reinstatement of incentive accruals and product mix. Adjusted gross margin remained relatively stable at 70.4%.
• Segment Performance: Protein Sciences remains the dominant segment (72% of sales). Diagnostics and Spatial Biology saw growth driven by molecular diagnostics and the integration of the Lunaphore acquisition.

Guidance, Outlook, and Risks

• Strategic Pillars: The company continues to focus on growing its core business, capitalizing on high-potential markets (cell and gene therapy), and expanding through innovation and acquisition.
• Acquisitions & Investments:
  • Completed acquisition of Lunaphore (Fiscal 2024) for $169.7 million.
  • Invested $15.0 million in Spear Bio (Fiscal 2025).
  • Hold 19.9% stake in Wilson Wolf; obligated to acquire remaining 80.1% by end of 2027 (or earlier upon milestone achievement), with a potential payment of approximately $1 billion.
• Divestiture: Announced a definitive agreement to sell the Exosome Diagnostics business for $15 million (including $5 million in stock), expected to close in Q1 Fiscal 2026.
• Capital Allocation: The company repurchased $275.7 million of stock in Fiscal 2025. A new $500 million share repurchase plan was approved in April 2025. Dividends paid were $50.4 million.
• Risks:
  • Geopolitical & Trade: Tariffs and trade tensions (particularly U.S.-China) may increase costs and disrupt supply chains.
  • Regulatory: Compliance with FDA, EU IVDR, and data privacy laws (GDPR, CCPA) remains a significant operational focus.
  • Acquisition Integration: Risks associated with integrating acquired businesses and achieving anticipated synergies.
  • Goodwill Impairment: Significant impairment charges were recorded in Fiscal 2025 related to assets held-for-sale.

Key Facts for Investor Verification

• Non-GAAP Adjustments: Verify the magnitude of the $41.8 million litigation charge and $80.5 million asset impairment, which significantly depressed GAAP earnings despite strong organic revenue growth.
• Wilson Wolf Obligation: Confirm the financial impact and timeline for the mandatory acquisition of the remaining 80.1% of Wilson Wolf, potentially requiring ~$1 billion in capital.
• Exosome Diagnostics Sale: Monitor the closing of the $15 million sale of the Exosome Diagnostics business and its impact on future revenue streams.
• Debt Capacity: Note the $346 million drawn on the $1 billion credit facility, leaving $654 million available for future acquisitions or operations.
• Segment Mix: Track the performance of the Diagnostics and Spatial Biology segment, which is growing faster than Protein Sciences but has lower gross margins (57.3% vs 75.6%).